Editas Medicine Announces Second Quarter 2019 Results and Update

    NEXT STORY
    Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD
    PREV STORY
    Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy

    PHAROAH Trial Results to-Date Show APL-2 Monotherapy Eliminated Transfusion Dependency and Improved Markers of ...

    author_avatar
    NASDAQ Market News

    MacroGenics to Present Phase 1 Data on Flotetuzumab, a CD123 x CD3 DART® Molecule, at 59th Annual ASH Meeting

    ROCKVILLE, MD, Nov. 01, 2017 (GLOBE NEWSWIRE) -- – MacroGenics, Inc. (NASDAQ: MGNX), a ...

    author_avatar
    NASDAQ Market News

    Graybug Vision Presents Preclinical Results for GB-401, a Potential Sustained-Delivery Treatment of up to Six Months for Primary Open Angle Glaucoma, at the American Glaucoma Society Annual Meeting

    author_avatar
    NASDAQ Market News